

# Sachiyo Yoshio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1370284/publications.pdf>

Version: 2024-02-01

47  
papers

1,052  
citations

430843

18  
h-index

454934

30  
g-index

50  
all docs

50  
docs citations

50  
times ranked

1932  
citing authors

#	ARTICLE	IF	CITATIONS
1	TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. <i>Hepatology</i> , 2013, 57, 1416-1425.	7.3	115
2	Human blood dendritic cell antigen 3 (BDCA3) <sup>+</sup> dendritic cells are a potent producer of interferon- $\beta$ in response to hepatitis C virus. <i>Hepatology</i> , 2013, 57, 1705-1715.	7.3	86
3	Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2016, 6, 35282.	3.3	77
4	Long noncoding RNA #32 contributes to antiviral responses by controlling interferon-stimulated gene expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 10388-10393.	7.1	76
5	Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2016, 6, 28814.	3.3	47
6	Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection. <i>Journal of Gastroenterology</i> , 2013, 48, 660-670.	5.1	41
7	Indoleamine 2,3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B. <i>Hepatology</i> , 2016, 63, 83-94.	7.3	38
8	Dysregulated Expression of the Nuclear Exosome Targeting Complex Component Rbm7 in Nonhematopoietic Cells Licenses the Development of Fibrosis. <i>Immunity</i> , 2020, 52, 542-556.e13.	14.3	33
9	Cytokine and chemokine signatures associated with hepatitis B surface antigen loss in hepatitis B patients. <i>JCI Insight</i> , 2018, 3, .	5.0	32
10	Association of serum IFN- $\gamma$ 3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2015, 50, 894-902.	5.1	30
11	Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2019, 54, 1007-1018.	5.1	29
12	Infection with flaviviruses requires BCLXL for cell survival. <i>PLoS Pathogens</i> , 2018, 14, e1007299.	4.7	28
13	Hepatocyte Factor JMJD5 Regulates Hepatitis B Virus Replication through Interaction with HBx. <i>Journal of Virology</i> , 2016, 90, 3530-3542.	3.4	27
14	Tumor necrosis factor- $\alpha$ -mediated hepatocyte apoptosis stimulates fibrosis in the steatotic liver in mice. <i>Hepatology Communications</i> , 2018, 2, 407-420.	4.3	27
15	MicroRNA-125b expression and intrahepatic metastasis are predictors for early recurrence after hepatocellular carcinoma resection. <i>Hepatology Research</i> , 2018, 48, 313-321.	3.4	25
16	Host-virus interactions in hepatitis B and hepatitis C infection. <i>Journal of Gastroenterology</i> , 2016, 51, 409-420.	5.1	23
17	Double-Stranded RNA Derived from Lactic Acid Bacteria Augments Th1 Immunity via Interferon- $\beta$ from Human Dendritic Cells. <i>Frontiers in Immunology</i> , 2018, 9, 27.	4.8	22
18	Liver disease secondary to congenital heart disease in children. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 651-666.	3.0	22

#	ARTICLE	IF	CITATIONS
19	Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy. <i>Hepatology</i> , 2022, 76, 112-125.	7.3	22
20	High serum interleukin-34 level is a predictor of poor prognosis in patients with non-viral hepatocellular carcinoma. <i>Hepatology Research</i> , 2019, 49, 1046-1053.	3.4	21
21	Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma. <i>Scientific Reports</i> , 2019, 9, 15788.	3.3	20
22	Ex vivo induction of IFN- $\gamma$ 3 by a TLR7 agonist determines response to Peg-IFN/Ribavirin therapy in chronic hepatitis C patients. <i>Journal of Gastroenterology</i> , 2014, 49, 126-137.	5.1	19
23	Myostatin as a fibroblast-activating factor impacts on postoperative outcome in patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2021, 51, 803-812.	3.4	18
24	USP15 Participates in Hepatitis C Virus Propagation through Regulation of Viral RNA Translation and Lipid Droplet Formation. <i>Journal of Virology</i> , 2019, 93, .	3.4	17
25	Cluster of Differentiation 44 Promotes Liver Fibrosis and Serves as a Biomarker in Congestive Hepatopathy. <i>Hepatology Communications</i> , 2021, 5, 1437-1447.	4.3	16
26	Effects of In-Hospital Exercise on Frailty in Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 194.	3.7	15
27	Impact of Immune Reconstitution-Induced Hepatic Flare on Hepatitis B Surface Antigen Loss in Hepatitis B Virus/Human Immunodeficiency Virus-1 Coinfected Patients. <i>Journal of Infectious Diseases</i> , 2021, 223, 2080-2089.	4.0	13
28	Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 936.	2.4	13
29	Increased Frequency of Dysfunctional Siglec-7 <sup>+</sup> CD57 <sup>+</sup> PD-1 <sup>+</sup> Natural Killer Cells in Patients With Non-alcoholic Fatty Liver Disease. <i>Frontiers in Immunology</i> , 2021, 12, 603133.	4.8	13
30	Effects of a low-intensity resistance exercise program on serum miR-630, miR-5703, and Fractalkine/CX3CL1 expressions in subjects with No exercise habits: A preliminary study. <i>Hepatology Research</i> , 2021, 51, 823-833.	3.4	11
31	Immune Determinants in the Acquisition and Maintenance of Antibody to Hepatitis B Surface Antigen in Adults After First-Time Hepatitis B Vaccination. <i>Hepatology Communications</i> , 2019, 3, 812-824.	4.3	8
32	Hepatitis Action Plan and Changing Trend of Liver Disease in Japan: Viral Hepatitis and Nonalcoholic Fatty Liver Disease. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2017, 7, 60-64.	0.5	8
33	Prolonged Gut Dysbiosis and Fecal Excretion of Hepatitis A Virus in Patients Infected with Human Immunodeficiency Virus. <i>Viruses</i> , 2021, 13, 2101.	3.3	8
34	Serum soluble sialic acid-binding immunoglobulin-like lectin-7 concentration as an indicator of liver macrophage activation and advanced fibrosis in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2020, 50, 466-477.	3.4	7
35	Phenotypic Characterization by Single-Cell Mass Cytometry of Human Intrahepatic and Peripheral NK Cells in Patients with Hepatocellular Carcinoma. <i>Cells</i> , 2021, 10, 1495.	4.1	7
36	Metabolic dysfunction-associated fatty liver disease directly related to liver fibrosis independent of insulin resistance, hyperlipidemia, and alcohol intake in morbidly obese patients. <i>Hepatology Research</i> , 2022, 52, 841-858.	3.4	7

#	ARTICLE	IF	CITATIONS
37	Blood angiopoietin-2 predicts liver angiogenesis and fibrosis in hepatitis C patients. BMC Gastroenterology, 2021, 21, 55.	2.0	6
38	Hepatitis C virus modulates signal peptide peptidase to alter host protein processing. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	6
39	Pro-angiogenic Tie2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma. International Journal of Cancer, 2017, 141, 1011-1017.	5.1	5
40	Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease. Immunological Medicine, 2021, 44, 175-186.	2.6	5
41	Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics. Global Health & Medicine, 2020, 2, 273-281.	1.4	4
42	Pharmacotherapy options for managing hepatitis B in children. Expert Opinion on Pharmacotherapy, 2021, 22, 449-467.	1.8	3
43	High Dose of Pegylated Interferon for the Treatment of Chronic Hepatitis B in Children Infected With Genotype C. JPCN Reports, 2020, 1, e005.	0.4	1
44	Abstract 569: Comprehensive analyses of serum biomarkers associating with the increase of pro-angiogenic Tie2-expressing monocytes in patients with hepatocellular carcinoma. , 2015, , .		0
45	Metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease: Which can better identify the populations with a high risk of cardiovascular disease?. Hepatology Research, 2021, 51, 1097-1099.	3.4	0
46	Increased frequency of PD-1+CD57+Siglec-7- dysfunctional NK cells in patients with nonalcoholic fatty liver disease.. Journal of Clinical Oncology, 2020, 38, 589-589.	1.6	0
47	Effects of SGLT2 inhibitor on tumor-releasing chemokines/cytokines in Hep3B and Huh7 cells. JGH Open, 2022, 6, 270-273.	1.6	0